Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)

NCT06353022 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT06353022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06353022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01)
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 26, 2024
Completion date
June 26, 2030
Enrollment
103 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma